HYATTSVILLE, MD – July 20, 2010 – Genomind, LLC participated in the FDA/CDRH Public Meeting: Oversight of Laboratory Developed Tests (LDTs) held in Hyattsville, MD on July 19-20, 2010. The FDA invited the public to present their perspectives on the patient and clinical considerations that should be taken into account when considering direct to consumer testing, greater oversight of LDTs, and the potential challenges faced by clinical laboratories. Genomind, LLC specializes in neuropsychiatric personalized medicine and was formed to facilitate the adoption of Personalized Medicine into psychiatry.
Genomind’s business strategy is to serve the commercial health care market, directed to psychiatric providers and payors and with supporting information to their patients.
About Genomind, LLC:
Genomind, LLC is a company specializing in neuropsychiatric personalized medicine and was formed to facilitate the adoption of Personalized Medicine into psychiatry by assisting physicians in the selection of appropriate medicine based on genetic information. Genomind was founded by Ronald I. Dozoretz, MD, in 2009, and the company is advised by a group of renowned experts in the fields of human genetics and neuropsychiatric medicine. More information is available at: www.genomind.com.
For more information, contact:
Marketing Manager, Genomind